Key statistics
On Friday, Vivoryon Therapeutics NV (05Y:FRA) closed at 2.39, 496.25% above the 52 week low of 0.40 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.36 |
---|---|
High | 2.39 |
Low | 2.36 |
Bid | 2.34 |
Offer | 2.44 |
Previous close | 2.34 |
Average volume | 2.30k |
---|---|
Shares outstanding | 26.07m |
Free float | 19.52m |
P/E (TTM) | -- |
Market cap | 62.30m EUR |
EPS (TTM) | -1.24 EUR |
Data delayed at least 15 minutes, as of Oct 18 2024 10:41 BST.
More ▼
Announcements
- Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event
- Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease
- Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association
- Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024
- Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease
- Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
- Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
- Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
- Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
More ▼